This bill requires the Centers for Medicare & Medicaid Services to issue guidance for state Medicaid programs on best practices to support individuals with major depressive disorder or other mental health conditions, including options that include pharmacogenetic testing.
To improve outcomes for Medicaid beneficiaries with major depressive 
              disorder or other mental health conditions.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. GUIDANCE RELATING TO MEDICAID COVERAGE OF GENETIC TESTING TO 
              IMPROVE OUTCOMES FOR BENEFICIARIES WITH MAJOR DEPRESSIVE 
              DISORDER OR OTHER MENTAL HEALTH CONDITIONS.

    Not later than 1 year after the date of enactment of this Act, the 
Administrator of the Centers for Medicare & Medicaid Services shall 
issue guidance for State Medicaid programs through a State Medicaid 
Director letter that specifies best practices to improve outcomes for 
individuals eligible for medical assistance under State Medicaid 
programs who have major depressive disorder or other mental health 
conditions. The guidance shall include coverage policy examples 
utilizing pharmacogenetic testing to support clinicians seeking 
medication options to treat patients and reduce trial and error from 
the Medicare program or from issuers of individual or group health 
insurance coverage.
                                 <all>
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Official Titles - Senate
Official Title as Introduced
A bill to improve outcomes for Medicaid beneficiaries with major depressive disorder or other mental health conditions.
Sen. Brown, Sherrod